. 2011 Jun;3(3):133–149. doi: 10.1177/1759720X11407540

Table 5.

Components of ACR response.

	OPTION						RADIATE

	TCZ 4 mg/kg + MTX		TCZ 8 mg/kg + MTX		Placebo + MTX		TCZ 4 mg/kg + MTX		TCZ 8 mg/kg + MTX		Placebo + MTX

Week 24	N = 213		N = 205		N = 204		N = 161		N = 170		N = 158
Component (mean)	Baseline	Week	Baseline	Week	Baseline	Week	Baseline	Week	Baseline	Week	Baseline	Week
		24^*		24^*		24		24^*		24^*		24
Number of tender joints (0–68)	33	19	32	14.5	33	25	31	21	32	17	30	30
		−7.0 (−10.0, −4.1)		−9.6 (−12.6, −6.7)				−10.8 (−14.6, −7.1)		−15.1 (−18.8, −11.4)
Number of swollen joints (0−66)	20	10	19.5	8	21	15	19.5	13	19	11	19	18
		−4.2 (−6.1, −2.3)		−6.2 (−8.1 −4.2)				−6.2 (−9.0, −3.5)		−7.2 (−9.9, −4.5)
Pain^†	61	33	60	30	57	43	63.5	43	65	33	64	48
		−11.0 (−17.0, −5.0)		−15.8 (−21.7, −9.9)				−12.4 (−22.1, −2.1)		−23.9 (−33.7, −14.1)
Patient global assessment^†	66	34	65	31	64	45	70	46	70	36	71	51
		−10.9 (−17.1, −4.8)		−14.9 (−20.9, −8.9)				−10.0 (−20.3, 0.3)		−17.4 (−27.8, −7.0)
Physician global assessment^†	64	26	64	23	64	32	66.5	39	66	28	67.5	43
		−5.6 (−10.5, −0.8)		−9.0 (−13.8, −4.2)				−10.5 (−18.6, −2.5)		−18.2 (−26.3, −10.0)
Disability index (HAQ)^‡	1.64	1.01	1.55	0.96	1.55	1.21	1.67	1.39	1.75	1.34	1.70	1.58
		−0.18 (−0.34, −0.02)		−0.21 (−0.37, −0.05)				−0.25 (−0.42, −0.09)		−0.34 (−0.51, −0.17)
CRP (mg/dl)	2.79	1.17	2.61	0.25	2.36	1.89	3.11	1.77	2.80	0.28	3.705	3.06
		−1.30 (−2.0, −0.59)		−2.156 (−2.86, −1.46)				−1.34 (−2.5, −0.15)		−2.52 (−3.72, −1.32)

MTX, methotrexate; TCZ, tocilizumab; ACR, American College of Rheumatology; HAQ, Health Assessment Questionnaire; CRP, C-reactive protein.

Data shown is mean at week 24, difference in adjusted mean change from baseline compared with placebo + MTX at week 24 and 95% confidence interval for that difference.

^†

Visual analog scale: 0 = best, 100 =worst.

^‡

Health Assessment Questionnaire: 0 = best, 3= worst; 20 questions; 8 categories: dressing and grooming, arising, eating, walking.